Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) has decided to increase its GMP1 manufacturing capacity for mRNA2 in Kaneka Eurogentec S.A. (Headquarters: Liege, Belgium; President: Lieven Janssens), a wholly owned group company in Europe.

We plan to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is around 5 times higher than the current capacity. Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO3, responding to the vigorous global demand for mRNA.

mRNA, which has been rapidly implemented in vaccines against COVID-19, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for genetic diseases, cancer and so on. The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.

Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA4 and has world-class technology for producing plasmid DNA5 and GMP manufacturing track records of over 25 years. They provide plasmid DNA, recombinant proteins, oligonucleotide6 and so on as drug substances for pharmaceutical companies worldwide. In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.

Regarding the priority area of Health Care, Kaneka will continue to provide solutions globally for health issues through the growth of its biopharmaceutical business.

Contact:

Email: www.eurogentec.com

(C) 2023 Electronic News Publishing, source ENP Newswire